An economic analysis of captopril in the treatment of diabetic nephropathy

Diabetes Care

Volumn 19, Issue 10, 1996, Pages 1051-1061

  Rodby, Roger A ^a,c   Lewis, Edmund J ^a   Firth, Louise M ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b Arthur D Little Inc   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MODEL; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 10144250935     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.10.1051     Document Type: Article

References (65)

1. The National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases: United States Renal Data System, 1993 Annual Data Report. March 1993, p. 55-67
2. U.S. Dept. of Health and Human Services, Public Health Service: Health, United States, 1992 and Healthy People 2000 Review. Washington, DC, 1994, p. 160
3. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035-2038, 1979
4. The National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases: United States Renal Data System, 1992 Annual Data Report. 1992
5. Andersen AR, Christiansen JS, Andersen J, Kreiner, S, Deckert T: Diabetic nephropathy in type 1 (insulin dependent) diabetes: an epidemiological study. Diabetologia 25:496-501, 1983
6. Tuttle KR, Stein JH, DeFronzo RA: The natural history of diabetic nephropathy. Semin Nephrol 10:184-193, 1990
7. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE: Is screening and intervention for microalbuminuria worthwhile in patients with insulin-dependent diabetes? Br Med J 306:1722-1725, 1993
8. Siegel JE, Krolewski AS, Warram JH, Weinstein MC: Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 3:S111-S119, 1992
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
10. Udvarhelyi SI, Colditz GA, Ria A, Epstein A: Cost-effectiveness and cost-benefit analysis in the medical literature. Ann Intern Med 116:238-244, 1992
11. Bentkover JD: CBA/CEA of pharmaceuticals: methods and applications. Drug Inf J 22:291-309, 1988
12. Deaths by selected causes and selected characteristics, 1990. Statistical Abstract of the United States, 1993. 127:92, 1993
13. Mahnensmith RL: Diabetic nephropathy: a comprehensive approach. Hosp Pract 3/95:65-80, 1993
14. Nelson RG, Newman JM, Knowler WC, Sievers ML, Kunzelman CL, Pettitt D, Moffett, CD, Teutsch AM, Bennett PH: Incidence of end-stage renal disease in type II (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 31:730-736, 1988
15. Cordonnier DJ, Zmirou D, Benhamou PY, Halimi S, Ledoux F, Guiserix J: Epidemiology, development and treatment of endstage renal failure in type II (non-insulin-dependent) diabetes mellitus. Diabetologia 36:1109-1112, 1993
16. Cowie CC, Port FR, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM: Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 321:1074-1079, 1989
17. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ: Chronic renal failure in non-insulin-dependent diabetes mellitus: a population-based study in Rochester, Minnesota. Ann Intern Med 111:788-796, 1989
18. The Division of Diabetes Translation, National Center for Chronic Disease Prevention, U.S. Department of Health and Human Services: Diabetes Surveillance, 1991. Washington, DC
19. Bailie GR, Eisele G: Continuous ambulatory peritoneal dialysis: a review of its mechanics, advantages, complications, and areas of controversy. Ann Pharmacother 26:1409-1420, 1992
20. Markell MS, Friedman EA: Diabetic nephropathy: management of the endstage patient. Diabetes Care 15:1226-1236, 1992
21. Mayers JD, Markell MS, Cohen LS, Hong J, Lundin P, Friedman EA: Vascular access surgery for maintenance hemodialysis variables in hospital stay. ASAIO Trans 38:113-115, 1992
22. Powe NR, Griffiths RI, de Lissovoy G, Anderson GF, Watson AJ, Greer JW, Herbert RJ, Eggers PW, Milam RA, Whelton PK: Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 268:1430-1440, 1992
23. Selby JV, FitzSimmons SC, Newman JM, Katz PP, Sepe S, Showstack J: The natural history and epidemiology of diabetic nephropathy-implications for prevention and control. JAMA 263:1954-1960, 1990
24. Rettig B, Teutsch SM: The incidence of end-stage renal disease in type I and type II diabetes mellitus. Diabetic Nephropathy 3:26-27, 1984
25. Raine AEG: Epidemiology, development and treatment of end-stage renal failure in type II (non-insulin-dependent) diabetic patients in Europe. Diabetologia 36:1099-1104, 1993
26. Boudreau RJ, Strony JT, duCret RP, Kuni CC, Wang Y, Wilson RF, Schwartz JS, Castaneda-Zuniga WR: Perfusion thallium imaging of type I diabetes patients with end-stage renal disease: comparison of oral and intravenous dipyridamole administration. Cardiac Radiol 175:103-105, 1990
27. Brown KA, Rimmer J, Haisch C: Noninvasive cardiac risk stratification of diabetic and nondiabetic uremic renal allograft candidates using dipyridamole-thallium-201 imaging and radionuclide ventriculography. Am J Cardiol 64:1017-1021, 1989
28. Camp AD, Garvin PJ, Hoff J, Marsh J, Byers SL, Chaitman BR: Prognostic value of intravenous dipyridamole thallium imaging in patients with diabetes mellitus considered for renal transplantation. Am J Cardiol 65:1459-1463, 1990
29. Manske CL, Wang Y, Rector T, Wilson RF, White CW: Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. Lancet 340:998-1002, 1992
30. Hirschl MM, Hein, G, Sunder-Plassmann G, Derfler K: Renal replacement therapy in type II diabetic patients: 10 years experience. Am J Kidney Dis 20:564-568, 1992
31. Manske CL, Thomas W, Wang Y, Wilson RF: Screening diabetic transplant candidates for coronary artery disease: identification of a low risk subgroup. Kidney Int 44:617-621, 1993
32. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T: Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 30:144-148, 1987
33. Parfrey PS, Harnett JD, Barre PE: The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 2:2-12, 1991
34. Philipson JD, Carpenter BJ, Itzkoff J, Hakala TR, Rosenthal JT, Taylor RJ, Puschett JB: Evaluation of cardiovascular risk for renal transplantation in diabetic patients. Am J Med 81:630-634, 1986
35. Wizeman V, Timio M, Alpert MA, Kramer W: Options in dialysis therapy: significance of cardiovascular findings. Kidney Int 43 (Suppl. 40):S85-S91, 1993
36. Department of Health and Human Services: Detailed Diagnoses and Procedures, National Hospital Discharge Survey, 1990. Washington, DC, DHHS/PUB/PHS-92-1744, 1992
37. Lemmers MJ, Barry JM: Major role for arterial disease in morbidity and mortality after kidney transplantation in diabetic recipients. Diabetes Care 14:295-301, 1991
38. American Diabetes Association: Direct and Indirect Costs of Diabetes in the United States in 1992. Alexandria, VA, American Diabetes Association, 1993, p. 1-27
39. Bentkover JD, Champion AH: Economic evaluation of alternative methods of treatment for diabetic foot ulcer patients: cost-effectiveness of platelet releasate and wound care clinics. Wounds 5:207-215, 1993
40. Palumbo PJ, Melton J III: Peripheral vascular disease and diabetes. In Diabetes in America. U.S. Department of Health and Human Services, Public Health Service at the National Institutes of Health. Washington, DC, 85-1468, 1985, p. XV-1-XV-17
41. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration, Pittsburgh epidemiology of diabetes complications study. Diabetes 39:1116-1124, 1990
42. American Medical Association: 1993 Physician's Current Procedural Terminology. 1992
43. Lorenz E: St. Anthony's DRG Working Guidebook 1993. St. Anthony Publishing.
44. Department of Health and Human Services, Health Care Financing Administration: 42 CFR Parts 400 and 405, Medicare program. Fee schedule for physicians' services for calendar year 1993. Federal Register 57(228):55994-56167, 1992
45. Department of Health and Human Services, Health Care Financing Administration: Calculation of prospective payment rates for FY 1993. Table 1A, national adjusted operating standardized amounts, labor/nonlabor. Federal Register 57:39834-39846, 1992
46. Health Care Financing Administration: 1993 Clinical Diagnostic Laboratory National Limitation Amounts. May 6, 1993
47. Health Care Financing Administration: ESRD Policy Division. May 13, 1993
48. Health Care Financing Administration: Letter. August 13, 1993
49. 1993 Drug Topics Red Book. Montvale, NJ, Medical Economics Data, p. 67-611
50. Levinsky NG: The organization of medical care, lessons from the Medicare end-stage renal program. N Engl J Med 329:1395-1399, 1993
51. Levinsky NG, Rettig RA: The Medicare end-stage renal disease program, a report from the Institute of Medicine. N Engl J Med 324:1143-1148, 1991
52. Douglas JB, Kenney GM, Miller TR: Which estimates of household production are best? J Forensic Econ 4:25-46, 1990
53. Rice DP, Hodgson TA, Kopstein AN: The economic cost of illness: a replication and update. Health Care Financ Rev 7:61-80, 1985
54. Deniston OL, Carpentier-Alting P, Kneisley J, Hawthorne VM, Port FK: Assessment of quality of life in end-stage renal disease. Health Services Res 24:555-578, 1989
55. Evans RW, Rader B, Manninen DL, and the Cooperative Multicenter EPO Clinical Trial Group: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263:825-830, 1990
56. Devins GM, Mandin H, Hons RB, Burgess ED, Klassen J, Taub K, Schorr S, Letourneau PK, Buckle S: Illness intrusiveness and quality of life in end-stage renal disease: comparison and stability across treatment modalities. Health Psychol 9:117-142, 1990
57. Morris PLP, Jones B: Life satisfaction across treatment methods for patients with endstage renal failure. Med J Aust 150:428-432, 1989
58. Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 312:555-559, 1985
59. National Institute of Diabetes and Digestive and Kidney Disease: Diabetes Statistics. NIH Publication No. 96-3926, October 1995
60. Dor A, Held PJ, Pauly MV: The Medicare cost of renal dialysis. Med Care 30:879-891, 1992
61. Health Care Financing Administration and Ernst & Young: DRG level tables. The DRG Handbook 1993. 1993, p. 1-61
62. Ritz ER, Stefanski A: Diabetic nephropathy in type II diabetes. Am J Kidney Dis 27:167-194, 1996
63. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118: 129-138, 1993
64. Viberti G, Mogesen CE, Groop LC, Pauls JF, for the European Microalbuminuria Study Group: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271:275-279, 1994
65. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetes mellitus patients with microalbuminuria. Br Med J 303:81-87, 1991